SOTIO's Dendritic Cell Vaccines Have Promise In Ovary And Lung Cancer

Cancer vaccine research has had its fair share of disappointing clinical trial results, but a central European company, Sotio AS, owned by the international finance group, PPF Group, presented positive Phase II results with two DCVAC vaccines, for potential use in ovarian and lung cancer, at the ASCO meeting on June 3, backing the promise of this emerging therapeutic category.

The use of DCVAC/OvCa in patients with ovarian cancer, and DCVAC/LuCa in patients with lung cancer, significantly decreased the risk of disease progression or death, researchers reported, and SOTIO is planning further clinical studies including a global Phase III study of DCVAC/OvCa